Ultime notizie per InspireMD (NASDAQ:NSPR) Azioni

InspireMD

InspireMD Inc is a United States based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System (MGuard Prime EPS). It generates the majority of the revenue from the sales of CGuard EPS which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The group operates in Italy, Germany, Russia and other countries.

InspireMD Inc

News

Management

NSPR

InspireMD Says CFO Craig Shore Has Decided To Retire From  Company After A Successor Is Identified

Lake Street analyst Frank Takkinen initiates coverage on InspireMD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NSPR#NASDAQ">NSPR</a>) with a Buy rating and announces Price Target of $5.

Price Target

Initiation

Analyst Ratings

Lake Street Initiates Coverage On InspireMD with Buy Rating, Announces Price Target of $5

InspireMD, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NSPR#NASDAQ">NSPR</a>), developer of the CGuard&#x2122; Embolic Prevention Stent System (EPS) for the prevention of stroke, today announced that the first patient has been enrolled in the company's CGUARDIANS II clinical trial evaluating its CGuard Prime Carotid Stent System in patients undergoing carotid artery stenting via the Transcarotid Artery Revascularization (TCAR) approach. The patient was enrolled by Dr. Patrick Muck at Good Samaritan Hospital, part of the TriHealth System in Cincinnati, Ohio. Dr. Muck serves as both the site principal investigator as well as a co-lead investigator of the CGUARDIANS II study.

InspireMD Enrolls First Patient in Clinical Trial for CGuard Carotid Stent System

CORRECTION: InspireMD Q1Numbers Are Old And Were Published Erroneously; Now Deleted

<h3>Gainers</h3>
<ul>
<li>Janux Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JANX#NASDAQ">JANX</a>) shares moved upwards by 67.4% to $67.26 during Tuesday's pre-market session. The market value of their outstanding shares is at $3.5 billion. </li>
<li>Coherus BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHRS#NASDAQ">CHRS</a>) shares rose 48.9% to $2.04. The company's market cap stands at $235.0 million. </li>
<li>Citius Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTOR#NASDAQ">CTOR</a>) stock moved upwards by 22.54% to $1.25. The market value of their outstanding shares is at $89.1 million. </li>
<li>Vir Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIR#NASDAQ">VIR</a>) shares rose 21.47% to $9.9. The market value of their outstanding shares is at $1.3 billion. </li>
<li>Kindly MD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KDLY#NASDAQ">KDLY</a>) shares rose 19.29% to $1.36. The company's market cap stands at $8.1 million. </li>
<li>PepGen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEPG#NASDAQ">PEPG</a>) stock rose 18.76% to $7.09. The company's market cap stands at $231.1 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Purple Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PPBT#NASDAQ">PPBT</a>) stock decreased by 27.7% to $6.07 during Tuesday's pre-market session. The market value of their outstanding shares is at $205.8 million. </li>
<li>Gelteq (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GELS#NASDAQ">GELS</a>) shares decreased by 24.36% to $2.89. The market value of their outstanding shares is at $27.2 million. </li>
<li>Sharps Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STSS#NASDAQ">STSS</a>) stock decreased by 16.51% to $2.8. The company's market cap stands at $5.0 million. </li>
<li>Revelation Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REVB#NASDAQ">REVB</a>) stock declined by 14.73% to $0.81. The market value of their outstanding shares is at $3.4 million. </li>
<li>InspireMD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NSPR#NASDAQ">NSPR</a>) shares fell 13.78% to $2.63. The company's market cap stands at $68.6 million. </li>
<li>Aptorum Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APM#NASDAQ">APM</a>) shares fell 12.31% to $0.74. The company's market cap stands at $4.0 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

CHRS

CTOR

GELS

JANX

KDLY

PEPG

PPBT

REVB

STSS

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

WIIM

InspireMD shares are trading higher after the company reported better-than-expected Q3 financial results.

InspireMD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NSPR#NASDAQ">NSPR</a>) reported quarterly losses of $(0.16) per share which beat the analyst consensus estimate of $(0.20) by 20 percent. The company reported quarterly sales of $1.810 million which beat the analyst consensus estimate of $1.740 million by 4.02 percent. This is a 16.32 percent increase over sales of $1.556 million the same period last year.

Earnings

Earnings Beats

InspireMD Q3 2024 GAAP EPS $(0.16) Beats $(0.20) Estimate, Sales $1.810M Beat $1.740M Estimate

ABOS

ABSI

ACNT

ACTG

AENT

AGEN

AIOT

AIRG

ALIT

ALTG

AMBC

AMPS

AMTX

APEI

AREB

ARIS

ARMN

ATRA

AUTL

Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share

AVDL

AXSM

AZTA

BHIL

BLDE

BLFS

BLTE

The Beachbody Company, Inc. Class A Common Stock

BODI

BRTX

BTMD

BTTR

BWAY

BXSL

BZFD

CAMT

CART

CATX

CAVA

CBAT

CBLL

CCLD

CGEN

CHGG

CHMI

CLSD

CNNE

CRNX

CRON

CRVS

CRWS

CVAC

CXAI

DAVA

DAVE

DRCT

DYAI

EARN

EGAN

ELMD

ETON

EVCM

EVGO

EYEN

FENG

FGEN

FIHL

FLNG

FOUR

FTCI

GENI

GENK

GMGI

GOVX

GRAL

GRDN

GROV

GRPN

GRVY

Earnings Scheduled For November 12, 2024

The new facility will ideally position the Company to support the anticipated U.S. launch and commercialization of the CGuard Prime carotid stent system in the first half of 2025, if approved.

InspireMD Reports Establishment Of Its Global Headquarters In Miami, Florida

InspireMD Says FDA Approved Investigational Device Exemption Application To Initiate CGUARDIANS II Pivotal Study Of CGuard Prime 80cm Carotid Stent System During TCAR Procedures

Piper Sandler analyst Adam Maeder reiterates InspireMD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NSPR#NASDAQ">NSPR</a>) with a Overweight and maintains $4.5 price target.

Reiteration

Piper Sandler Reiterates Overweight on InspireMD, Maintains $4.5 Price Target

Health Care

General

InspireMD Has Submitted A Premarket Approval Application To FDA Seeking Approval For The CGuard Prime Carotid Stent System, US Commercial Launch Anticipated In H1 2025, If Approved

InspireMD Q2 2024 GAAP EPS $(0.22) Misses $(0.20) Estimate, Sales $1.739M Miss $1.740M Estimate

Biotech

Macro Economic Events

Economics

InspireMD Presents One-Year Follow-Up Results From C-GUARDIANS US IDE Trial Of CGuard At LINC 2024 On May 28 At 8:53 a.m. EDT

InspireMD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NSPR#NASDAQ">NSPR</a>) reported quarterly losses of $(0.21) per share which missed the analyst consensus estimate of $(0.15) by 40 percent. This is a 60.38 percent increase over losses of $(0.53) per share from the same period last year. The company reported quarterly sales of $1.511 billion which beat the analyst consensus estimate of $1.384 million by 109.08K percent. This is a 121.85K percent increase over sales of $1.239 million the same period last year.

Earnings Misses

InspireMD Q1 2024 GAAP EPS $(0.21) Misses $(0.15) Estimate, Sales $1.511B Beat $1.384M Estimate

InspireMD Announces Abstract Of One-year Follow-up Results From C-GUARDIANS U.S. Investigational Device Exemption Clinical Trial Accepted For Presentation At LINC 2024

InspireMD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NSPR#NASDAQ">NSPR</a>) reported quarterly losses of $(0.16) per share which beat the analyst consensus estimate of $(0.20) by 20 percent. This is a 73.33 percent increase over losses of $(0.60) per share from the same period last year. The company reported quarterly sales of $1.76 million which beat the analyst consensus estimate of $1.63 million by 8.04 percent. This is a 71.64 percent increase over sales of $1.03 million the same period last year.

InspireMD Q4 EPS $(0.16) Beats $(0.20) Estimate, Sales $1.76M Beat $1.63M Estimate

<h3>Companies Reporting Before The Bell</h3>
&bull; CTS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTS#NYSE">CTS</a>) is estimated to report quarterly earnings at $0.14 per share on revenue of $708.85 million.
&bull; Foot Locker (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FL#NYSE">FL</a>) is likely to report quarterly earnings at $0.32 per share on revenue of $2.28 billion.
&bull; JD.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JD#NASDAQ">JD</a>) is likely to report quarterly earnings at $0.63 per share on revenue of $42.16 billion.
&bull; Super Group (SGHC) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SGHC#NYSE">SGHC</a>) is expected to report quarterly earnings at $0.01 per share on revenue of $326.63 million.
&bull; Sotherly Hotels (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOHO#NASDAQ">SOHO</a>) is projected to report earnings for its fourth quarter.
&bull; Thor Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THO#NYSE">THO</a>) is estimated to report quarterly earnings at $0.67 per share on revenue of $2.27 billion.
&bull; Nexxen International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEXN#NASDAQ">NEXN</a>) is expected to report quarterly earnings at $0.10 per share on revenue of $86.80 million.
&bull; VersaBank (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VBNK#NASDAQ">VBNK</a>) is likely to report quarterly earnings at $0.35 per share on revenue of $22.43 million.
&bull; Abercrombie &amp; Fitch (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANF#NYSE">ANF</a>) is expected to report quarterly earnings at $2.83 per share on revenue of $1.43 billion.
&bull; Brown Forman Inc Class B Common Stock (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BF#NYSE">BF</a>) is expected to report quarterly earnings at $0.56 per share on revenue of $1.12 billion.
&bull; WAVE Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WVE#NASDAQ">WVE</a>) is likely to report quarterly loss at $0.23 per share on revenue of $19.86 million.
&bull; Yatsen Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YSG#NYSE">YSG</a>) is projected to report earnings for its fourth quarter.
&bull; iShares $ Short Duration Corp Bond UCITS ETF USD (Dist) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SDIG#NASDAQ">SDIG</a>) is projected to report quarterly loss at $0.98 per share on revenue of $22.21 million.
&bull; InspireMD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NSPR#NASDAQ">NSPR</a>) is expected to report quarterly loss at $0.19 per share on revenue of $1.63 million.
&bull; Korn Ferry (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KFY#NYSE">KFY</a>) is estimated to report quarterly earnings at $0.99 per share on revenue of $658.50 million.
&bull; Kamada (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KMDA#NASDAQ">KMDA</a>) is projected to report quarterly earnings at $0.05 per share on revenue of $37.71 million.
&bull; PureCycle Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCT#NASDAQ">PCT</a>) is projected to report quarterly loss at $0.23 per share on revenue of $180 thousand.
&bull; Xeris Biopharma Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XERS#NASDAQ">XERS</a>) is estimated to report quarterly loss at $0.10 per share on revenue of $43.55 million.
&bull; Genius Sports (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GENI#NYSE">GENI</a>) is expected to report quarterly loss at $0.07 per share on revenue of $126.13 million.
&bull; Adaptimmune Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADAP#NASDAQ">ADAP</a>) is estimated to report quarterly loss at $0.10 per share on revenue of $20.47 million.
&bull; NeueHealth (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEUE#NYSE">NEUE</a>) is estimated to report quarterly loss at $4.16 per share on revenue of $283.44 million.
&bull; Campbell Soup (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CPB#NYSE">CPB</a>) is projected to report quarterly earnings at $0.77 per share on revenue of $2.44 billion.
&bull; EVgo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVGO#NASDAQ">EVGO</a>) is projected to report quarterly loss at $0.18 per share on revenue of $44.03 million.
&bull; Hippo Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIPO#NYSE">HIPO</a>) is estimated to report quarterly loss at $2.01 per share on revenue of $55.25 million.
&bull; BrainsWay (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BWAY#NASDAQ">BWAY</a>) is expected to report quarterly loss at $0.01 per share on revenue of $8.42 million.
&bull; Fusion Fuel Green (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HTOO#NASDAQ">HTOO</a>) is estimated to report quarterly loss at $0.40 per share on revenue of $1.75 million.
&bull; European Wax Center (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EWCZ#NASDAQ">EWCZ</a>) is projected to report quarterly earnings at $0.07 per share on revenue of $54.08 million.
&bull; REV Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/REVG#NYSE">REVG</a>) is likely to report quarterly earnings at $0.15 per share on revenue of $579.42 million.
&bull; United Natural Foods (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNFI#NYSE">UNFI</a>) is likely to report quarterly loss at $0.01 per share on revenue of $7.87 billion.
&bull; Berry Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRY#NASDAQ">BRY</a>) is projected to report quarterly earnings at $0.24 per share on revenue of $182.37 million.
&bull; Brown Forman Inc Class A Common Stock (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BF#NYSE">BF</a>) is estimated to report earnings for its third quarter.
&bull; Trinity Cap (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRIN#NASDAQ">TRIN</a>) is estimated to report quarterly earnings at $0.54 per share on revenue of $46.42 million.
&bull; Antero Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AR#NYSE">AR</a>) is expected to report earnings for its fourth quarter.
<h3>Companies Reporting After The Bell</h3>
&bull; Descartes Systems Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DSGX#NASDAQ">DSGX</a>) is likely to report quarterly earnings at $0.37 per share on revenue of $144.29 million.
&bull; Emergent BioSolutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBS#NYSE">EBS</a>) is estimated to report quarterly loss at $0.19 per share on revenue of $293.53 million.
&bull; Fortuna Silver Mines (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FSM#NYSE">FSM</a>) is estimated to report quarterly earnings at $0.10 per share on revenue of $261.00 million.
&bull; Inovio Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INO#NASDAQ">INO</a>) is estimated to report quarterly loss at $1.27 per share on revenue of $340 thousand.
&bull; Companhia Siderurgica (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SID#NYSE">SID</a>) is likely to report quarterly earnings at $0.19 per share on revenue of $2.32 billion.
&bull; Global X Silver Miners ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SIL#NYSE">SIL</a>) is expected to report quarterly earnings at $0.10 per share on revenue of $44.09 million.
&bull; TDCX (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDCX#NYSE">TDCX</a>) is expected to report quarterly earnings at $0.09 per share on revenue of $121.92 million.
&bull; Vermilion Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VET#NYSE">VET</a>) is expected to report quarterly earnings at $0.52 per share on revenue of $440.69 million.
&bull; VSE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSEC#NASDAQ">VSEC</a>) is expected to report quarterly earnings at $0.75 per share on revenue of $234.91 million.
&bull; Victoria&#39;s Secret (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VSCO#NYSE">VSCO</a>) is projected to report quarterly earnings at $2.47 per share on revenue of $2.09 billion.
&bull; SandRidge Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SD#NYSE">SD</a>) is likely to report earnings for its fourth quarter.
&bull; CPS Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPSH#NASDAQ">CPSH</a>) is projected to report earnings for its fourth quarter.
&bull; Grove Collaborative Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GROV#NYSE">GROV</a>) is expected to report quarterly loss at $0.23 per share on revenue of $61.45 million.
&bull; KLX Energy Services Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLXE#NASDAQ">KLXE</a>) is projected to report quarterly earnings at $0.01 per share on revenue of $212.97 million.
&bull; Culp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CULP#NYSE">CULP</a>) is likely to report quarterly loss at $0.16 per share on revenue of $59.49 million.
&bull; GEN Restaurant Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GENK#NASDAQ">GENK</a>) is projected to report quarterly earnings at $0.03 per share on revenue of $43.95 million.
&bull; MISTRAS Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MG#NYSE">MG</a>) is estimated to report quarterly earnings at $0.15 per share on revenue of $174.28 million.
&bull; IDT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IDT#NYSE">IDT</a>) is projected to report earnings for its second quarter.
&bull; FRP Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRPH#NASDAQ">FRPH</a>) is projected to report earnings for its fourth quarter.
&bull; Global Water Resources (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GWRS#NASDAQ">GWRS</a>) is estimated to report quarterly earnings at $0.05 per share on revenue of $12.00 million.
&bull; NeoGames (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NGMS#NASDAQ">NGMS</a>) is projected to report quarterly loss at $0.07 per share on revenue of $54.53 million.
&bull; Hamilton Beach Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HBB#NYSE">HBB</a>) is estimated to report earnings for its fourth quarter.
&bull; Amplify Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMPY#NYSE">AMPY</a>) is likely to report quarterly earnings at $0.18 per share on revenue of $76.22 million.
&bull; Pampa Energia (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PAM#NYSE">PAM</a>) is likely to report quarterly loss at $0.09 per share on revenue of $421.19 million.
&bull; Talphera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLPH#NASDAQ">TLPH</a>) is estimated to report quarterly loss at $0.20 per share on revenue of $280 thousand.
&bull; Cyngn (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYN#NASDAQ">CYN</a>) is expected to report quarterly loss at $0.12 per share on revenue of $70 thousand.
&bull; HighPeak Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HPK#NASDAQ">HPK</a>) is expected to report quarterly earnings at $0.65 per share on revenue of $339.52 million.
&bull; BRC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRCC#NYSE">BRCC</a>) is estimated to report quarterly loss at $0.01 per share on revenue of $123.75 million.
&bull; MDxHealth (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDXH#NASDAQ">MDXH</a>) is likely to report quarterly loss at $0.11 per share on revenue of $18.14 million.
&bull; NACCO Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NC#NYSE">NC</a>) is estimated to report earnings for its fourth quarter.
&bull; Enhabit (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EHAB#NYSE">EHAB</a>) is expected to report quarterly earnings at $0.03 per share on revenue of $260.16 million.
&bull; Intrepid Potash (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IPI#NYSE">IPI</a>) is projected to report quarterly loss at $0.06 per share on revenue of $43.57 million.
&bull; OneSpan (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OSPN#NASDAQ">OSPN</a>) is projected to report quarterly earnings at $0.03 per share on revenue of $58.26 million.
&bull; Honest Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HNST#NASDAQ">HNST</a>) is estimated to report quarterly loss at $0.08 per share on revenue of $84.14 million.
&bull; SilverCrest Metals (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SILV#AMEX">SILV</a>) is expected to report quarterly earnings at $0.10 per share on revenue of $44.09 million.
&bull; AudioEye (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEYE#NASDAQ">AEYE</a>) is estimated to report quarterly loss at $0.11 per share on revenue of $7.93 million.
&bull; comScore (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCOR#NASDAQ">SCOR</a>) is likely to report quarterly earnings at $0.20 per share on revenue of $97.69 million.
&bull; Viemed Healthcare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VMD#NASDAQ">VMD</a>) is projected to report quarterly earnings at $0.10 per share on revenue of $50.00 million.
&bull; Kewaunee Scientific (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KEQU#NASDAQ">KEQU</a>) is projected to report earnings for its third quarter.
&bull; ChromaDex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDXC#NASDAQ">CDXC</a>) is estimated to report quarterly loss at $0.03 per share on revenue of $20.98 million.
&bull; Whitestone REIT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WSR#NYSE">WSR</a>) is projected to report earnings for its fourth quarter.
&bull; Aris Water Solutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARIS#NYSE">ARIS</a>) is estimated to report earnings for its fourth quarter.
&bull; OrthoPediatrics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KIDS#NASDAQ">KIDS</a>) is expected to report quarterly loss at $0.28 per share on revenue of $37.73 million.
&bull; Invesco National AMT-Free Municipal Bond ETFo (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PZA#NYSE">PZA</a>) is estimated to report earnings for its fourth quarter.
&bull; Hudson Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HDSN#NASDAQ">HDSN</a>) is projected to report quarterly earnings at $0.08 per share on revenue of $40.28 million.
&bull; Stabilis Solutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLNG#NASDAQ">SLNG</a>) is projected to report earnings for its fourth quarter.
&bull; Airgain (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIRG#NASDAQ">AIRG</a>) is projected to report quarterly loss at $0.20 per share on revenue of $10.00 million.
&bull; Finance of America (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FOA#NYSE">FOA</a>) is projected to report quarterly loss at $0.08 per share on revenue of $63.22 million.
&bull; Yext (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YEXT#NYSE">YEXT</a>) is likely to report quarterly earnings at $0.07 per share on revenue of $100.24 million.
&bull; TriplePoint Venture Gwth (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPVG#NYSE">TPVG</a>) is expected to report quarterly earnings at $0.48 per share on revenue of $33.13 million.
&bull; CompoSecure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMPO#NASDAQ">CMPO</a>) is estimated to report quarterly earnings at $0.23 per share on revenue of $96.49 million.
&bull; Kodiak Gas Services (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KGS#NYSE">KGS</a>) is expected to report quarterly earnings at $0.29 per share on revenue of $222.52 million.
&bull; Cyber Hornet S&amp;P 500 and Bitcoin 75/25 Strategy ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZZZ#NASDAQ">ZZZ</a>) is likely to report quarterly earnings at $0.53 per share on revenue of $247.43 million.
&bull; Ellington Residential (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EARN#NYSE">EARN</a>) is projected to report quarterly earnings at $0.23 per share on revenue of $2.46 million.
&bull; Spire Global (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPIR#NYSE">SPIR</a>) is expected to report quarterly loss at $0.72 per share on revenue of $29.34 million.
&bull; Lulus Fashion Lounge (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LVLU#NASDAQ">LVLU</a>) is estimated to report quarterly loss at $0.10 per share on revenue of $73.40 million.
&bull; Rush Street Interactive (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RSI#NYSE">RSI</a>) is likely to report quarterly loss at $0.03 per share on revenue of $178.56 million.
&bull; Hamilton Insurance Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HG#NYSE">HG</a>) is expected to report quarterly earnings at $0.65 per share on revenue of $15.30 million.
&bull; Infinera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INFN#NASDAQ">INFN</a>) is likely to report quarterly earnings at $0.09 per share on revenue of $437.34 million.
&bull; Riley Exploration Permian (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/REPX#AMEX">REPX</a>) is estimated to report quarterly earnings at $1.60 per share on revenue of $94.75 million.
&bull; Zymeworks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZYME#NASDAQ">ZYME</a>) is expected to report quarterly loss at $0.43 per share on revenue of $15.45 million.
&bull; Miller Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MLR#NYSE">MLR</a>) is projected to report earnings for its fourth quarter.
This article was generated by Benzinga&#39;s automated content engine and reviewed by an editor.

ADAP

AEYE

AMPY

BRCC

CDXC

CMPO

CPSH

CULP

DSGX

EHAB

EWCZ

FRPH

GWRS

HDSN

HIPO

HNST

HTOO

INFN

KEQU

KIDS

KLXE

KMDA

LVLU

MDXH

NEUE

NEXN

NGMS

OSPN

PowerShares Insured Municipal Bond Portfolio

REPX

REVG

SCOR

SDIG

SGHC

SILV

SLNG

SOHO

SPIR

TDCX

TLPH

TPVG

TRIN

UNFI

VBNK

VSCO

VSEC

XERS

YEXT

ZYME

Earnings Scheduled For March 6, 2024

InspireMD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NSPR#NASDAQ">NSPR</a>) is set to give its latest quarterly earnings report on Wednesday, 2024-03-06. Here's what investors need to know before the announcement.
Analysts estimate that InspireMD will report an earnings per share (EPS) of $-0.19. 
InspireMD bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Historical Earnings Performance</h3>
Last quarter the company missed EPS by $0.00, which was followed by a 2.99% drop in the share price the next day.
Here's a look at InspireMD's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2023</th>
<th>Q2 2023</th>
<th>Q1 2023</th>
<th>Q4 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.15</td>
<td>-0.30</td>
<td>-0.68</td>
<td>-0.84</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.15</td>
<td>-0.24</td>
<td>-0.53</td>
<td>-0.60</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-3.0%</td>
<td>0.0%</td>
<td>-9.0%</td>
<td>7.000000000000001%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1709665372_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of InspireMD were trading at $2.57 as of March 04. Over the last 52-week period, shares are up 126.76%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<a href="https://www.benzinga.com/quote/NSPR/earnings">To track all earnings releases for InspireMD visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Preview: InspireMD's Earnings

InspireMD Appoints Principal Investigators For Its Upcoming C-GUARDIANS II Clinical Trial Of SwitchGuard Neuroprotection System

InspireMD ( ($NSPR) ) just unveiled an update. InspireMD, Inc. has reported record revenue for Q3 2024, driven by its CGuard Prime carotid stent sy...

InspireMD Achieves Record Q3 Revenue with CGuard Success

InspireMD Inc ( ($NSPR) ) has released its Q3 earnings. Here is a breakdown of the information InspireMD Inc presented to its investors. InspireMD ...

InspireMD Inc. Reports Q3 2024 Financial Results

InspireMD Inc (NSPR) has disclosed a new risk, in the Accounting & Financial Operations category. InspireMD Inc. faces considerable uncertainty reg...

InspireMD Inc. Faces Financial Uncertainty Amidst Ongoing Losses and Cash Flow Challenges

InspireMD ( ($NSPR) ) has issued an update. InspireMD has appointed Scott R. Ward, a seasoned executive with a rich history in medical technology a...

InspireMD Strengthens Leadership with Scott R. Ward Appointment

InspireMD (NSPR) announced that the first patient has been enrolled in the company's CGUARDIANS II clinical trial evaluating its CGuard Prime Carot...

InspireMD announces first patient enrolled in CGUARDIANS II study

InspireMD ( ($NSPR) ) just unveiled an announcement. InspireMD, Inc. has enrolled its first patient in the CGUARDIANS II clinical trial, a signific...

InspireMD Advances CGuard Prime with New Clinical Trial

Lake Street analyst Frank Takkinen initiated coverage of InspireMD (NSPR) with a Buy rating and $5 price target InspireMD's CGuard carotid artery s...

InspireMD initiated with a Buy at Lake Street

Comments

InspireMD

Notizie

Ultime notizie per InspireMD (NASDAQ:NSPR) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO